Growth hormone intrauterine & thin endometrium of IVF patients

Evaluation the effects of intracavitary Gh in thin endometrium of IVF patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20091012002576N28

Enrollment

Registered

2023-07-01

Start date

2023-06-25

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility of uterine origin

Interventions

Intervention 1: Intervention group: intracavitary growth hormone will be injected by IUI catheter one cm above internal OS cervix, 0.5 cc of Gh(Cinatrop Pen, cinagen company) at the 6th day of esterog

Eligibility

Sex/Gender

Female

Age

20 Years to 45 Years

Inclusion criteria

Inclusion criteria: History IVF failure due to thin endometrium Having good quality embryo

Exclusion criteria

Exclusion criteria: Severe male infertility BMI>30 Uncontrolled hypothyroidism User of corticosteroids User of glucose control agents CNS tumors Uterine malformations Asherman syndrome Cavity distorting lesions Severe endometriosis Liver disease

Design outcomes

Primary

Measure	Time frame
Endometrial thickness. Timepoint: At the day of starting progesterone. Method of measurement: Transvaginal sonogram.	—

Secondary

Measure	Time frame
Chemical pregnancy. Timepoint: Two weeks after embryo transfer. Method of measurement: Beta HCG titer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Davari Tanha

Tehran University of Medical Sciences

Fatedavtanha@gmail.com+98 21 8880 0115

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026